CellGenTech
CellGenTech is a bio-venture company dedicated to developing regenerative medicine, cell therapy, and gene therapy treatments. They focus on creating safe and effective therapies using proprietary technology of transduction of human adipocytes, especially for intractable and rare diseases. Their mission is to improve patients' quality of life by providing innovative cell-based medicines, particularly for diseases caused by genetic deficiencies. They actively collaborate with academia and industry partners to advance their pipeline of gene and cell therapies.
Industries
Nr. of Employees
small (1-50)
CellGenTech
Chiba-dai Inohana Innovation Plaza #208, 1-8-15, Inohana, Chuo-ku, Chiba-city, Chiba 260-0856 Japan
Products
LCAT gene-engineered autologous adipocyte therapy for familial LCAT deficiency
Autologous adipocytes transduced to express LCAT enzyme intended to restore enzyme activity in patients with familial LCAT deficiency; clinical research has been conducted and peer-reviewed results published.
Factor VIII secretion program using engineered adipocytes (preclinical)
Preclinical development of adipocytes engineered to secrete Factor VIII as a potential approach for hemophilia A, supported by non-clinical studies toward clinical trial readiness.
α-Galactosidase secretion program using engineered adipocytes (preclinical)
Preclinical program applying engineered adipocytes to secrete α-galactosidase for potential treatment of Fabry disease and related lysosomal storage disorders; partnership and licensing pathways pursued.
Insulin-secreting adipocyte program (preclinical)
Preclinical studies assessing implantation of insulin-expressing adipocytes in diabetic animal models to regulate blood glucose; efficacy reversible upon implant removal demonstrated in animals.
LCAT gene-engineered autologous adipocyte therapy for familial LCAT deficiency
Autologous adipocytes transduced to express LCAT enzyme intended to restore enzyme activity in patients with familial LCAT deficiency; clinical research has been conducted and peer-reviewed results published.
Factor VIII secretion program using engineered adipocytes (preclinical)
Preclinical development of adipocytes engineered to secrete Factor VIII as a potential approach for hemophilia A, supported by non-clinical studies toward clinical trial readiness.
α-Galactosidase secretion program using engineered adipocytes (preclinical)
Preclinical program applying engineered adipocytes to secrete α-galactosidase for potential treatment of Fabry disease and related lysosomal storage disorders; partnership and licensing pathways pursued.
Insulin-secreting adipocyte program (preclinical)
Preclinical studies assessing implantation of insulin-expressing adipocytes in diabetic animal models to regulate blood glucose; efficacy reversible upon implant removal demonstrated in animals.
Services
Co-development and licensing arrangements to advance engineered-adipocyte programs from preclinical stages through clinical development and commercialization.
Execution of non-clinical in vitro and in vivo studies to generate proof-of-concept, efficacy and safety data supporting clinical trial applications.
On-site development of manufacturing workflows and CMC documentation for production of autologous gene-modified adipocyte therapeutics, with planning for scale-up and third-party manufacturing partnerships.
Administration and execution support for projects funded by national agencies to advance translational research and preclinical-to-clinical development.
Co-development and licensing arrangements to advance engineered-adipocyte programs from preclinical stages through clinical development and commercialization.
Execution of non-clinical in vitro and in vivo studies to generate proof-of-concept, efficacy and safety data supporting clinical trial applications.
On-site development of manufacturing workflows and CMC documentation for production of autologous gene-modified adipocyte therapeutics, with planning for scale-up and third-party manufacturing partnerships.
Administration and execution support for projects funded by national agencies to advance translational research and preclinical-to-clinical development.
Expertise Areas
- Ex vivo adipocyte-based gene therapy
- Cell-based therapeutic development and CMC
- Regenerative medicine clinical development and regulatory submissions
- Preclinical in vitro and in vivo evaluation and safety assessment
Key Technologies
- Ex vivo gene transduction
- Retroviral vector-mediated gene transfer
- Primary adipocyte expansion and autologous transplantation
- GMP-compliant cell manufacturing and master cell bank generation
News & Updates
The technology of 'Genetically Modified Human Adipocytes GMAC' will be introduced via a video at Expo 2025 in Osaka, Japan, by the Ministry of Health, Labour and Welfare. The event is scheduled from June 21 to June 29, 2025, at EXPO Messe, Osaka.
The results of a clinical study of LCAT-GMAC for familial LCAT deficiency, jointly conducted by CellGenTech and Chiba University, were published in Heliyon. The study demonstrated the safety and efficacy of the first genetically modified human adipocytes GMAC implantation.
CellGenTech was selected for a development subsidy project by AMED to conduct non-clinical studies for clinical trials of Factor VIII gene-transduced adipocytes for hemophilia A.
CellGenTech signed a joint development and license agreement with Kyorin Pharmaceutical for GMAC targeting Fabry disease.
Toho Holdings announced an investment in CellGenTech to enhance its initiatives in gene therapy drugs and regenerative medicine products.
Nissui Pharmaceutical announced an investment in CellGenTech to accelerate development of regenerative medicine support technologies.
The technology of 'Genetically Modified Human Adipocytes GMAC' will be introduced via a video at Expo 2025 in Osaka, Japan, by the Ministry of Health, Labour and Welfare. The event is scheduled from June 21 to June 29, 2025, at EXPO Messe, Osaka.
The results of a clinical study of LCAT-GMAC for familial LCAT deficiency, jointly conducted by CellGenTech and Chiba University, were published in Heliyon. The study demonstrated the safety and efficacy of the first genetically modified human adipocytes GMAC implantation.
CellGenTech was selected for a development subsidy project by AMED to conduct non-clinical studies for clinical trials of Factor VIII gene-transduced adipocytes for hemophilia A.
CellGenTech signed a joint development and license agreement with Kyorin Pharmaceutical for GMAC targeting Fabry disease.
Toho Holdings announced an investment in CellGenTech to enhance its initiatives in gene therapy drugs and regenerative medicine products.
Nissui Pharmaceutical announced an investment in CellGenTech to accelerate development of regenerative medicine support technologies.